Wegovy vs Mounjaro - Cheapest UK Price from £124.99

Our Pricing

Wegovy vs Mounjaro: Which Weight Loss Injection Is Right for You?

When comparing Wegovy vs Mounjaro, UK patients often face a difficult choice between two highly effective GLP-1 receptor agonist medications for weight loss. Both treatments have demonstrated exceptional results in clinical trials, but they differ in mechanism, efficacy, cost, and side effect profiles. Understanding these differences is essential for making an informed decision with your prescriber about which medication may be most suitable for your weight loss journey.

How Wegovy vs Mounjaro Work: Understanding the Mechanism Difference

The fundamental difference in Wegovy vs Mounjaro lies in their pharmacological mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a single gut hormone to reduce appetite and slow gastric emptying [1]. Mounjaro, on the other hand, contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates two hormonal pathways simultaneously, potentially offering enhanced metabolic benefits [2].

This dual-action mechanism in Mounjaro may explain why clinical trials have shown slightly superior weight loss outcomes compared to single-pathway medications. The GIP component works synergistically with GLP-1 to improve insulin sensitivity, reduce food intake, and increase energy expenditure. However, both medications require subcutaneous injection once weekly and are subject to prescriber approval following clinical assessment by a UK-registered healthcare professional.

In our clinical experience at Cured Pharmacy, patients respond individually to each medication. Some find Wegovy's single-pathway approach sufficient for their weight loss goals, whilst others benefit from Mounjaro's dual mechanism, particularly if they have additional metabolic concerns such as insulin resistance or prediabetes.

Wegovy vs Mounjaro Clinical Trial Results: Which Delivers Better Weight Loss?

When evaluating Wegovy vs Mounjaro based on clinical evidence, the STEP trials for semaglutide and SURMOUNT trials for tirzepatide provide robust comparative data. The STEP 1 trial demonstrated that Wegovy users achieved an average weight loss of 14.9% of body weight over 68 weeks [1]. In contrast, the SURMOUNT-1 trial showed Mounjaro users at the highest dose (15mg) achieved an average weight loss of 20.9% over 72 weeks [2].

These results suggest Mounjaro may offer superior weight loss outcomes in clinical trial settings, though individual responses vary considerably. A head-to-head comparison study published in JAMA Internal Medicine found tirzepatide users lost approximately 5kg more on average than semaglutide users over 40 weeks [3]. However, it's crucial to note that trial populations may not reflect real-world UK patient demographics, and factors such as adherence, lifestyle modifications, and individual metabolism significantly influence outcomes.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar emphasises that the 'better' medication depends entirely on individual patient factors including BMI, comorbidities, tolerance to side effects, and budget considerations. Both medications require gradual dose escalation and ongoing clinical monitoring to optimise safety and efficacy.

Real-World Effectiveness in UK Patients

Beyond controlled trial environments, real-world evidence from UK prescribing data suggests both Wegovy and Mounjaro demonstrate clinically meaningful weight loss when combined with dietary and lifestyle interventions. NICE guidance acknowledges both medications as effective options for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, subject to specific criteria and prescriber discretion [4].

Wegovy vs Mounjaro UK Price Comparison: Which Offers Better Value?

Cost is a significant consideration when comparing Wegovy vs Mounjaro in the UK market. At Cured Pharmacy, Wegovy is available from £124.99 per month, whilst Mounjaro starts from £124.99 per month, making Wegovy the more affordable option for budget-conscious patients. New patients can save an additional £20 off their first order using code Weightlossnew, bringing Wegovy to just £124.99 for the initial month.

When evaluating value, it's essential to consider not just upfront cost but also efficacy, tolerability, and long-term adherence. Whilst Mounjaro carries a higher price point, some patients may find the potentially greater weight loss justifies the additional expense. Conversely, Wegovy's lower cost and well-established safety profile make it an accessible entry point for many UK patients beginning their weight loss journey.

Cured Pharmacy offers transparent upfront pricing with no hidden fees, and all prices include clinical consultation with a UK-registered prescriber, prescription processing, and discreet home delivery. Our pricing represents the cheapest UK price available for genuine, MHRA-licensed weight loss medications, with no compromise on clinical safety or regulatory compliance.

Switching Between Wegovy vs Mounjaro: Clinical Considerations and Process

Many UK patients consider switching between Wegovy vs Mounjaro based on efficacy, side effects, or cost factors. Switching between GLP-1 medications requires careful clinical oversight and should only be undertaken following consultation with a UK prescriber. The transition typically involves discontinuing one medication and initiating the other at its lowest starting dose, even if you were previously on a higher maintenance dose [5].

Common reasons for switching from Wegovy to Mounjaro include inadequate weight loss response after 3-6 months at therapeutic doses, or a desire to trial the dual-agonist mechanism for potentially enhanced results. Conversely, patients may switch from Mounjaro to Wegovy due to cost considerations, supply constraints, or better tolerability of the single-pathway GLP-1 approach.

At Cured Pharmacy, our clinical team evaluates each switch request individually, considering your weight loss history, current dose, side effect profile, and medical history. The switching process requires a new clinical assessment to ensure the alternative medication remains appropriate and safe for your circumstances. Most patients can transition smoothly between medications, though a brief adjustment period for side effects is common as your body adapts to the new treatment.

Optimal Timing for Medication Switches

Clinical guidance suggests allowing at least 3-4 months at a therapeutic maintenance dose before concluding a medication is ineffective. Premature switching may prevent you from experiencing the full benefits of dose escalation. Our prescribers at Cured Pharmacy assess weight loss trajectory, adherence to lifestyle modifications, and tolerability before recommending a medication change.

Side Effects Profile: Wegovy vs Mounjaro Tolerability Comparison

When comparing Wegovy vs Mounjaro for side effects, both medications share a similar adverse event profile dominated by gastrointestinal symptoms. The most common side effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, typically most pronounced during dose escalation phases [1][2]. Clinical trial data suggests these side effects are generally mild to moderate and diminish over time as tolerance develops.

Some evidence suggests Mounjaro may cause slightly higher rates of gastrointestinal side effects due to its dual-agonist mechanism, though comparative studies show no statistically significant difference in discontinuation rates between the two medications [3]. Individual tolerance varies considerably—some patients find Wegovy gentler on their digestive system, whilst others report better tolerability with Mounjaro despite its dual action.

Serious adverse events are rare with both medications but include potential risks of pancreatitis, gallbladder disease, and thyroid C-cell tumours (based on rodent studies). Both Wegovy and Mounjaro are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. All patients require thorough medical screening before initiation, which is conducted as part of the clinical assessment at Cured Pharmacy.

Managing Side Effects During Treatment

Regardless of whether you choose Wegovy or Mounjaro, side effect management strategies remain consistent: eat smaller, more frequent meals, avoid high-fat foods, stay well-hydrated, and follow the prescribed dose escalation schedule without rushing. Our clinical team provides ongoing support and can adjust dosing schedules if side effects become problematic.

Making Your Choice: Wegovy vs Mounjaro Decision Framework for UK Patients

Deciding between Wegovy vs Mounjaro requires balancing multiple factors specific to your individual circumstances. Consider Wegovy if you prioritise affordability (from £124.99 at Cured Pharmacy), prefer a well-established medication with extensive real-world safety data, or have budget constraints that make Mounjaro's higher cost prohibitive. Wegovy remains an excellent first-line option for most UK patients seeking clinically proven weight loss medication.

Consider Mounjaro if you have previously used Wegovy without achieving adequate weight loss, have significant metabolic comorbidities that may benefit from dual GIP/GLP-1 action, or are willing to invest in potentially superior weight loss outcomes as demonstrated in head-to-head trials. Mounjaro may be particularly suitable for patients with higher baseline BMI or those who have struggled with other weight loss interventions.

Ultimately, the decision between Wegovy vs Mounjaro should be made collaboratively with a UK-registered prescriber who can evaluate your complete medical history, weight loss goals, budget, and individual risk factors. At Cured Pharmacy, our clinical assessment process ensures you receive personalised recommendations based on current MHRA and NICE guidance. Both medications require ongoing commitment to dietary and lifestyle modifications for optimal results, and neither should be viewed as a standalone solution to weight management.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. [accessed 15 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy and Mounjaro: Product Information and Prescribing Guidance. MHRA Public Assessment Reports. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.